Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 3/20 | 0.33 |
| ▸ | CNR2 | P34972 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GCGR | P47871 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3376167 | 0.81 | LIPG (0.38) | LIPGKCNH2NR1H2NR1H3CNR1 | |
| SCHEMBL20979870 | 0.75 | KCNH2 (0.44) | TLR8KCNH2CNR1CNR2 | |
| SCHEMBL1782895 | 0.74 | KCNH2 (0.39) | LIPGKCNH2EPHX2CNR1CNR2 | |
| SCHEMBL18796184 | 0.74 | CYP1A2 (0.41) | TLR8KCNH2CNR1CNR2POLB | |
| SCHEMBL18796151 | 0.74 | CYP1A2 (0.41) | TLR8KCNH2CNR1CNR2POLB | |
| SCHEMBL9206225 | 0.73 | APOBEC3G (0.48) | APOBEC3G | |
| SCHEMBL7284382 | 0.73 | CNR2 (0.41) | TLR8NR1H2NR1H3CNR1CNR2 | |
| SCHEMBL9033192 | 0.72 | NPC1 (0.36) | NR1H2NR1H3CNR1CNR2POLB | |
| SCHEMBL2004591 | 0.72 | FAAH (0.39) | LIPGEPHX2CNR1CNR2 | |
| SCHEMBL2004589 | 0.72 | FAAH (0.39) | LIPGEPHX2CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110695-B2 | Compounds and compositions containing silicon and/or other heteroatoms and/or metals and methods of making and using them | WELKER MARK E (US) | 2012-02-07 | — | — | US | disclosed |
| US-20100056801-A1 | Compounds And Compositions Containing Silicon And/Or Other Heteroatoms And/Or Metals And Methods of Making And Using Them | WELKER MARK E | 2010-03-04 | — | — | US | disclosed |
| WO-2008054718-A2 | COMPOUNDS AND COMPOSITIONS CONTAINING SILICON AND/OR OTHER HETEROATOMS AND/OR METALS AND METHODS OF MAKING AND USING THEM | WAKE FOREST UNIVERSITY (US) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056801-A1 | Compounds And Compositions Containing Silicon And/Or Other Heteroatoms And/Or Metals And Methods of Making And Using Them | CA6, SOD1, CA1 | LIPG 4036/4885TLR8 4787/4885APOBEC3G 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.